title: Comparison between theophylline and an adenosine non-blocking xanthine in acute asthma.
abstract: Enprofylline, a drug without adenosine antagonism and theophylline, a potent adenosine antagonist, were compared, double-blind, randomized, in acute asthma (n = 33). The drugs were given intravenously as loading over 10 min followed by maintenance infusion for 24 h. Mean final plasma levels were very high with enprofylline (14 mg.l), and larger than calculated with theophylline (16 mg.l). Seven patients had maximum levels of enprofylline ranging between 16 and 42 mg.l. Extreme plasma levels of enprofylline were not associated with any theophylline-like central nervous system excitatory effects related to seizure-inducing ability. Some irregularities in the heart rhythm did not raise clinical problems and no significant difference between enprofylline and theophylline was recorded. At 1 h patients on enprofylline (mean plasma level: 5.7 mg.l) and theophylline (12.2 mg.l) had improved their peak expiratory flow rates by 31% and 15% (p less than 0.05), respectively. The improvement in lung function after 24 hours did not differ between treatments suggesting that the high levels of enprofylline were supramaximal for its anti-asthma effects in this situation. In conclusion, with enprofylline it is demonstrated that an adenosine non-blocking xanthine derivative may lack CNS-excitatory effects, but be more potent than theophylline in the treatment of acute asthma.
authors.affiliation: Department of Lung Medicine, Region Hospital of Trondheim, Norway.
authors.forename: J S
authors.initials: JS
authors.lastname: Vilsvik
authors.forename: C G
authors.initials: CG
authors.lastname: Persson
authors.forename: T
authors.initials: T
authors.lastname: Amundsen
authors.forename: E
authors.initials: E
authors.lastname: Brenna
authors.forename: T
authors.initials: T
authors.lastname: Naustdal
authors.forename: U
authors.initials: U
authors.lastname: Syvertsen
authors.forename: L
authors.initials: L
authors.lastname: Storstein
authors.forename: A G
authors.initials: AG
authors.lastname: Källén
authors.forename: G
authors.initials: G
authors.lastname: Eriksson
authors.forename: S
authors.initials: S
authors.lastname: Holte
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D011897:Random Allocation; D013806:Theophylline / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D014970:Xanthines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001993:Bronchodilator Agents; D014970:Xanthines; D013806:Theophylline; C034347:enprofylline